No. Data generated under RUO conditions cannot be retrospectively reclassified as GCP/GCLP-compliant. If the regulatory intent of a study changes, the bioanalytical work must be restarted under a properly controlled framework from sample receipt onward.
This is a common and avoidable situation. Lipotype addresses it proactively by completing a regulatory tier assessment with every new customer before project initiation – ensuring the right quality framework is in place from day one, regardless of whether a clinical submission is immediately anticipated.